India’s Diabetes and Obesity Drug Market Set for a Price Revolution
The Indian pharmaceutical landscape is bracing for a significant shift as the patent for semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, expires on March 20th. This expiration paves the way for a surge of more affordable generic versions, promising substantial savings for patients battling diabetes and obesity.
The End of Market Exclusivity
For years, Novo Nordisk has held exclusive rights to market Ozempic and Wegovy in India. However, with the patent expiring, Indian drug manufacturers are now free to produce and sell generic alternatives. Several companies, including Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories, have already received regulatory approvals and are prepared to launch their versions immediately. Zydus Lifesciences, Alkem Laboratories, Natco Pharma, Mankind Pharma, Lupin and Ajanta Pharma are also poised to enter the market.
Significant Price Reductions Expected
Currently, Ozempic and Wegovy in India can cost between Rs 10,000–15,000 per month for starter doses. Industry experts predict a price reduction of approximately 50% following the patent expiry. This translates to a potential saving of Rs 4,000–6,000 per patient each month, or Rs 50,000-70,000 annually.
Recent Entrants and Brand Strategies
Sun Pharmaceutical Industries will offer two branded options: Sematrinity for type 2 diabetes and Noveltreat for chronic weight management. Dr. Reddy’s Laboratories is launching Obeda, having previously been authorized for manufacturing and export. The initial wave is expected to include over a dozen brands within weeks, with many more to follow, intensifying price competition.
The Growing Burden of Diabetes in India
The timing of this patent expiration is particularly crucial given the escalating diabetes crisis in India. According to the Metabolic non-communicable disease health report of India, over 100 million individuals currently live with diabetes, a number projected to exceed 150 million by 2050. This surge is driven by factors like urbanization, aging populations, increasing obesity, and lifestyle changes.
Impact on Novo Nordisk and the GLP-1 Market
India represents one of the first major markets where Ozempic is losing patent exclusivity. This will serve as a critical test for Novo Nordisk, demonstrating how quickly generic competition can impact pricing power within the rapidly expanding GLP-1 (glucagon-like peptide-1) segment.
FAQ
Q: When will generic semaglutide be available in India?
A: Generic versions will be available from March 21st, 2026.
Q: How much cheaper will generic semaglutide be?
A: Industry experts anticipate a price reduction of around 50%.
Q: Which companies are launching generic semaglutide in India?
A: Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Zydus Lifesciences, Alkem Laboratories, Natco Pharma, Mankind Pharma, Lupin and Ajanta Pharma are among the companies launching generic versions.
Q: What is semaglutide used for?
A: Semaglutide is used to treat type 2 diabetes and chronic weight management.
Did you know? India is facing one of the world’s fastest-growing diabetes burdens, highlighting the importance of affordable treatment options.
Pro Tip: Consult with your healthcare provider to determine if semaglutide or a generic alternative is the right treatment option for you.
Explore more articles on Business and Personal Finance on NDTV Profit to stay informed about the latest developments in the pharmaceutical industry.
